NYBCe and Chan Zuckerberg Biohub have teamed up to develop an iPSC platform using cord blood for regenerative medicine.

      **Summary:** The New York Blood Center Enterprises (NYBCe) and the Chan Zuckerberg Biohub are joining forces to create induced pluripotent stem cell (iPSC) lines from umbilical cord blood, utilizing NYBCe's collection of over 30,000 units, which includes rare HLA-homozygous donors, alongside Biohub's expertise in reprogramming immune cells. The goal is to provide shared research resources for regenerative medicine, disease modeling, and cell therapy, addressing a major challenge in the field: bridging laboratory biology with scalable, immune-compatible treatments.

      Most of the umbilical cord blood collected at birth is thrown away. After being clamped and cut, the tissue is discarded as medical waste, along with the stem cells it holds—cells that are immunologically naive, genetically diverse, and capable of being reprogrammed into virtually any human cell type. On April 30, the New York Blood Center Enterprises, which has the world’s oldest public cord blood bank, announced a partnership with the Chan Zuckerberg Biohub, funded by Mark Zuckerberg and Priscilla Chan. This collaboration aims to transform discarded cells into a library of iPSC lines from cord blood that are broadly compatible with human immune systems, serving as shared research resources for regenerative medicine, disease modeling, and cell therapy. While not a major pharmaceutical deal—with no billion-dollar agreements or IPO filings—it aims to address a fundamental issue in cell therapy: the divide between lab-created biology and the biology that can be mass-produced and delivered to patients.

      **Understanding the Biology:** Induced pluripotent stem cells are adult cells reprogrammed to act like embryonic stem cells, able to differentiate into any cell type. Shinya Yamanaka’s pioneering work, which earned him the Nobel Prize in 2012, demonstrated that introducing four specific genes can revert mature cells to a pluripotent state. Since then, iPSCs have been the basis of numerous experimental therapies, including those targeting Parkinson’s disease, heart failure, and cancer. Over 115 clinical trials involving pluripotent stem cell therapies are ongoing worldwide, treating more than 1,200 patients with no significant safety issues reported. The FDA has given its Regenerative Medicine Advanced Therapy (RMAT) designation to more than 60 products, including the first iPSC-derived therapy to receive both Fast Track and RMAT status—a treatment for Parkinson’s disease by iRegene. The iPSC market is expected to expand from $2.6 billion in 2026 to $4.1 billion by 2031.

      The challenge lies not in the efficacy of iPSCs, but in their origin. Most iPSC lines used in research come from skin or blood cells collected from individual donors, resulting in lines with varied genetic backgrounds and immune profiles. If transplanted into a patient, these cells are often seen as foreign by the recipient's immune system, necessitating lifelong immunosuppressive medication, which carries risks. Creating patient-specific iPSC lines for every individual is not only costly but time-consuming. The field requires a middle ground: standardized, well-characterized iPSC lines compatible with larger segments of the population without the need for personalized production for each patient. This is where cord blood becomes relevant.

      **The Resource:** The National Cord Blood Program, under NYBCe's Lindsley F. Kimball Research Institute, was established in 1992 by Dr. Pablo Rubinstein with funding from the National Heart, Lung, and Blood Institute. It was the first public cord blood bank and has maintained an inventory of over 30,000 cord blood units consented for clinical transplantation and research over the years. This program produced HEMACORD, the first FDA-licensed cord blood product, and its units have facilitated thousands of transplants for patients with blood cancers and other disorders lacking a matched bone marrow donor. Cord blood cells are immunologically privileged, being less likely to induce graft-versus-host disease compared to adult bone marrow, which is why cord blood transplants can handle greater degrees of HLA mismatch. A phase 2 trial published in April 2026 in the Journal of Clinical Oncology showed that a pooled cord blood product achieved a 96 percent one-year survival rate in leukemia patients without severe graft-versus-host disease.

      Among NYBCe's inventory are cord blood units from donors with homozygous genotypes at crucial HLA loci, meaning they possess identical copies of immune-compatibility genes. These rare units are invaluable, as iPSC lines derived from them would be compatible with a significant portion of the population. Research from Japan, where the iPSC haplobanking concept began, showed that lines from about 50 homozygous donors could match over 90 percent of the Japanese population. The NYBCe-Biohub partnership will leverage these homozygous units, alongside LFKRI's expertise in high-resolution cell sorting and hematology, to develop iPSC lines with maximum translational potential.

      **